Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly to research and develop innovative cancer treatments.
Under the new agreement, the parties will leverage AdvanCell's proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly's drug candidate programs to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
AdvanCell said its capability and infrastructure enable it to develop rapidly and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.
"This collaboration with Lilly represents a significant milestone for AdvanCell, recognising our company as one of the leaders in the Pb-212 targeted alpha therapy space," said Andrew Adamovich, AdvanCell CEO. "By combining our groundbreaking isotope production capabilities, our team's expertise and infrastructure with Lilly's pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship."
Jacob Van Naarden, the president of Lilly Oncology, added, "Partnering with AdvanCell aligns with our commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we work to bring meaningful new treatments for patients."
